Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $23.7778.

A number of equities analysts have recently issued reports on the company. Morgan Stanley upped their price objective on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday. Stifel Nicolaus increased their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. UBS Group boosted their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th.

Insider Buying and Selling

In related news, insider Rajeev A. Modi acquired 4,500 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $21.33 per share, with a total value of $95,985.00. Following the completion of the purchase, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Robert M. Vanhimbergen bought 6,950 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $21.64 per share, with a total value of $150,398.00. Following the purchase, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. The trade was a 5.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 43,450 shares of company stock valued at $937,883 over the last three months. 0.89% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. SJS Investment Consulting Inc. raised its holdings in Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares during the last quarter. Huntington National Bank increased its position in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares during the period. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after purchasing an additional 2,414 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.5%

Shares of Elanco Animal Health stock opened at $24.54 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $24.84. The firm has a market cap of $12.19 billion, a PE ratio of 409.07, a PEG ratio of 3.41 and a beta of 1.87. The company has a 50 day simple moving average of $22.55 and a two-hundred day simple moving average of $19.78.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.13 EPS. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.